Transfemoral tricuspid valve replacement and one-year outcomes: the TRISCEND study.
Susheel KodaliRebecca T HahnRaj R MakkarMoody MakarCharles J DavidsonJyothy J PuthumanaFiras E ZahrScott ChadderdonNeil FamGeraldine OngPradeep YadavVinod ThouraniMani A VannanWilliam W O'NeillDee Dee WangDidier TchétchéNicolas DumonteilLaurent BonfilsLaurent LepageRobert SmithPaul A GrayburnRahul P SharmaChristiane L HaeffeleVasilis BabaliarosPatrick T GleasonSammy ElmariahIgnacio Inglessis-AzuajeJonathan PasseriHoward C HerrmannFrank E SilvestryScott LimDale FowlerJohn G WebbRobert MossThomas ModineStephane LafitteAzeem LatibEdwin HoYthan GoldbergPinak ShahCharles NymanJosep Rodés-CabauElisabeth BédardNicolas BruggerAnna SanninoMichael J MackMartin B LeonStephan Windeckernull nullPublished in: European heart journal (2023)
In an elderly, highly comorbid population with ≥moderate TR, patients receiving transfemoral EVOQUE transcatheter TV replacement had sustained TR reduction, significant increases in stroke volume and cardiac output, and high survival and low hospitalization rates with improved clinical, functional, and quality-of-life outcomes to one year. Funded by Edwards Lifesciences, TRISCEND ClinicalTrials.gov number, NCT04221490.
Keyphrases
- transcatheter aortic valve replacement
- aortic valve
- transcatheter aortic valve implantation
- aortic stenosis
- aortic valve replacement
- mitral valve
- atrial fibrillation
- left ventricular
- type diabetes
- heart failure
- coronary artery disease
- high intensity
- metabolic syndrome
- skeletal muscle
- insulin resistance
- blood brain barrier
- subarachnoid hemorrhage